
    
      A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study
      to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as
      Measured by Positron Emission Tomography (PET), in Patients with Parkinson's Disease
    
  